Effect of locosamide as an add-on therapy in the management of dissociative disorders

TL;DR

This study found that adding lacosamide to standard treatment improves symptoms and quality of life in patients with dissociative disorders.

Contribution

The study demonstrates lacosamide's effectiveness as an add-on therapy for dissociative disorders.

Findings

50.67% of patients in the intervention group showed symptom improvement compared to 10.67% in the control group.

Quality of life improved significantly in the lacosamide group, with fewer patients reporting poor or satisfactory outcomes.

Abstract

The role of lacosamide (LCM) as add on treatment modality in dissociative disorders (DD) is of interest. It was a randomized control
trial in which 300 patients diagnosed with dissociative disorders having treatment for the dissociative disorders were included. They
were divided into two groups. Group one consisted of intervention group in which LCM was also administered along with conventional
psychiatric medication for different dissociative disorders. Group two consisted of control group where the patients of dissociative
disorders were found to have conventional medication. There was analysis of improvements in recovery of symptoms and quality of life.
There was statistically significant increase in excellent, very good, good and fair quality of life and decrease in poor and satisfactory
quality of life in intervention group after drug intervention. It was observed that symptoms of the patients improved in 50.67% cases in
intervention group and 10.67% cases in control group. There was greater improvement in recovery of symptoms and quality of life in
patients of DD in which LCM was administered as add on medication.